Background: Depression is among one of the most common mental health disorders in the United States. Though several different treatments exist, not all work effectively for patients. Psilocybin, a serotonin receptor agonist, may be able to provide another route of therapeutic relief for some individuals who suffer from depression.
Methods: Using Dr. Michael Bornstein’s comprehensive meta-analysis software, we were able to compile data from three different studies that administered psilocybin to clinically depressed individuals. The study participants received several levels of treatment and placebo trials. Few viable studies exist due to the legal restriction of psilocybin.
Results: Psilocybin showed a large and significant effect size (Hedges’ g = 1.71 to 2.39) when used in the treatment of depression and depressive symptoms.
Conclusion: These findings suggest that psilocybin may be used as an alternative treatment for depression in some individuals. Further research is needed to understand the true efficacy, effect, and potential benefits of psilocybin for depression and other mental disorders.
Keywords: psilocybin, depression, psychedelics, major depressive disorder, treatment-resistant depression
This is a metadata-only record.
- Event location
- Event date
25 March 2022
- Date submitted
20 July 2022
- Additional information
Dr. Clayton Teem